Characteristics of patients by baseline eGFR.

<p>* HCVAb+ or HBsAg+</p><p>Characteristics of patients by baseline eGFR.</p

Rates and hazard ratios of CVD associated with eGFR from fitting a Cox regression model.

<p>^(a) Adjusted for age, gender mode of HIV transmission, ethnicity and calendar year of baseline</p><p>^(b) Adjusted for smoking, diabetes mellitus,previous AIDS diagnosis, blood pressure lowering drugs,lipid lowering drugs, total cholesterol, blood glucose levelsand high density lipoprotein cholesterol</p><p>^(c) Adjusted for ART-status, baseline CD4, CD8, nadir CD4, baseline HIV-RNA and co-infection with hepatitis B/C</p><p>^(d) Adjusted for factors in footnotes a-c.</p><p>Rates and hazard ratios of CVD associated with eGFR from fitting a Cox regression model.</p

Risk of AIDS-events during follow-up according to basal eGFR.

<p>Risk of AIDS-events during follow-up according to basal eGFR.</p

Rates and hazard ratios of AIDS associated with eGFR from fitting a Cox regression model.

<p>^(a) Adjusted for age, gender mode of HIV transmission, ethnicity and calendar year of baseline</p><p>^(b) Adjusted for smoking, diabetes mellitus,previous AIDS diagnosis, blood pressure lowering drugs,lipid lowering drugs, total cholesterol, blood glucose levelsand high density lipoprotein cholesterol</p><p>^(c) Adjusted for ART-status, baseline CD4, CD8, nadir CD4, baseline HIV-RNA and co-infection with hepatitis B/C</p><p>^(d) Adjusted for factors in footnotes a-c.</p><p>Rates and hazard ratios of AIDS associated with eGFR from fitting a Cox regression model.</p

Risk of cerebro-cardiovascular disease during follow-up according to basal eGFR.

<p>Risk of cerebro-cardiovascular disease during follow-up according to basal eGFR.</p

Hazard ratios of AIDS from fitting a Cox regression model (other factors).

<p>Hazard ratios of AIDS from fitting a Cox regression model (other factors).</p

Hazard ratios of CCVD from fitting a Cox regression model (other factors).

<p>Hazard ratios of CCVD from fitting a Cox regression model (other factors).</p

Evolution of (a-d) blood lipids and (e) renal function as by estimated GFR (CKD-EPI) over the 48 study weeks by randomization arm.

<p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p

GUSTA flow diagram.

<p>GUSTA flow diagram.</p

Proportion of individuals with virological failure over the complete follow-up available until the time of study interruption in the intention to treat population.

<p>Arm S = study arm (switch to maraviroc + darunavir/ritonavir); Arm C = continuation arm (continuation of previous 3-drug therapy).</p